{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T18:16:12Z","timestamp":1777918572427,"version":"3.51.4"},"reference-count":37,"publisher":"SAGE Publications","issue":"1","license":[{"start":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T00:00:00Z","timestamp":1641427200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"FPRC Onlus 5 X 1000 Fondi Ministero della Salute"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Tumori"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n                    <jats:title>Objective:<\/jats:title>\n                    <jats:p>Neoadjuvant chemotherapy has become the preferred treatment in HER2-positive early breast cancer. Several trials investigated the neoadjuvant efficacy of dual HER2 blockade with anthracycline-free chemotherapy, whereas few data are available on single-agent trastuzumab and anthracycline-based regimens, which represent the standard of care in the adjuvant setting. This phase II, single-arm trial assessed anthracycline-based chemotherapy and trastuzumab as neoadjuvant treatment for high-risk HER2-positive breast cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>\n                      Forty-three patients with stage II\u2013III HER2-positive breast cancer were treated with 4 courses of neoadjuvant 5-fluorouracil 600 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , epirubicin 90 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      , cyclophosphamide 600 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      (FEC \u00d74) every 21 days, followed by 12 courses of weekly paclitaxel 80 mg\/m\n                      <jats:sup>2<\/jats:sup>\n                      and trastuzumab 2 mg\/Kg IV (loading dose 4 mg\/kg).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>Pathologic complete response (pCR) was observed in 22 (51%) of 43 patients. After a median follow-up of 6 years, the 5-year disease-free survival and overall survival were 85.8% (95% confidence interval 75.9%\u201397%) and 89.6% (80.4%\u201399.8%), respectively. A temporary decrease in left ventricular ejection fraction was observed in two patients. No cardiac death or congestive heart failure occurred. One patient died due to febrile neutropenia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions:<\/jats:title>\n                    <jats:p>FEC \u00d74 followed by paclitaxel and trastuzumab was associated with high pCR rates and favorable long-term outcomes. However, this regimen was associated with relevant hematologic toxicity.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/03008916211067568","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T06:35:47Z","timestamp":1641450947000},"page":"71-78","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":3,"title":["Anthracycline, taxane, and trastuzumab-based neoadjuvant chemotherapy in HER2-positive early breast cancer: phase II trial"],"prefix":"10.1177","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4720-2497","authenticated-orcid":false,"given":"Benedetta","family":"Conte","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Montemurro","sequence":"additional","affiliation":[{"name":"Multidisciplinary Outpatient Oncology Clinic, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessia","family":"Levaggi","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"Blondeaux","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Molinelli","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Cardinali","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Poggio","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genova, U.O. Oncologia Medica 2, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulia","family":"Buzzatti","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, IRCCS Ospedale Policlinico San Martino, Genova, U.O. Oncologia Medica 2, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Bighin","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Breast Unit, IRCCS Ospedale Policlinico San Martino, Genova, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matteo","family":"Lambertini","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy"},{"name":"Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucia","family":"Del Mastro","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy"},{"name":"Department of Medical Oncology, U.O.C. Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2022,1,6]]},"reference":[{"key":"bibr1-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz173"},{"key":"bibr2-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.03399"},{"key":"bibr3-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.55.5730"},{"key":"bibr4-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62422-8"},{"key":"bibr5-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1612645"},{"key":"bibr6-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1814017"},{"key":"bibr7-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61847-3"},{"key":"bibr8-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70320-1"},{"key":"bibr9-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.04.038"},{"key":"bibr10-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.0823"},{"key":"bibr11-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70336-9"},{"key":"bibr12-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)00163-7"},{"key":"bibr13-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.62.1268"},{"key":"bibr14-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70411-X"},{"key":"bibr15-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt182"},{"key":"bibr16-03008916211067568","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejca.2017.10.021","volume":"89","author":"Schneeweiss A","year":"2018","journal-title":"Eur J Cancer"},{"key":"bibr17-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2016.07.017"},{"key":"bibr18-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30570-9"},{"key":"bibr19-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.07.032"},{"key":"bibr20-03008916211067568","doi-asserted-by":"crossref","unstructured":"Gianni L, Eiermann W, Semiglazov V, et al. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort. 2010; 375: 8.","DOI":"10.1016\/S0140-6736(09)61964-4"},{"key":"bibr21-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(14)70080-4"},{"key":"bibr22-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70502-3"},{"key":"bibr23-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.30274"},{"key":"bibr24-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.29808"},{"key":"bibr25-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2015.64.6620"},{"key":"bibr26-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.50.9984"},{"key":"bibr27-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2019.10.023"},{"key":"bibr28-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2013.831"},{"key":"bibr29-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.0868"},{"key":"bibr30-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)62048-1"},{"key":"bibr31-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00542-2"},{"key":"bibr32-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30716-7"},{"key":"bibr33-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz055"},{"key":"bibr34-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.8823"},{"key":"bibr35-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.01204"},{"key":"bibr36-03008916211067568","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1703643"},{"key":"bibr37-03008916211067568","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence - SEER Research Data, 9 Registries, November 2019 Sub (1975-2017) - Linked To County Attributes - Time Dependent (1990-2017) Income\/Rurality, 1969-2017 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, released April 2020, based on the November 2019 submission. SEER. https:\/\/seer.cancer.gov\/statfacts\/html\/breast.html."}],"container-title":["Tumori Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916211067568","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/03008916211067568","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/03008916211067568","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T18:42:10Z","timestamp":1777660930000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/03008916211067568"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,6]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["10.1177\/03008916211067568"],"URL":"https:\/\/doi.org\/10.1177\/03008916211067568","relation":{},"ISSN":["0300-8916","2038-2529"],"issn-type":[{"value":"0300-8916","type":"print"},{"value":"2038-2529","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,1,6]]}}}